RevOpsis Secures $16.5 Million Seed Funding to Advance First-in-Class Tri-Specific Therapy for Neovascular AMD Treatment

Investigational New Drug enabling studies initiated: On track for first-in-human trials in 2025 SAN CARLOS, Calif., April 25, 2024 /PRNewswire/ — RevOpsis Therapeutics, a next-generation biopharmaceutical company spearheading innovation in ophthalmic therapies, announced today it has…

Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks


ADVERTISEMENT — Advertise With Biotech Networks